We estimate the impact of government-mandated proof of vaccination requirements for access to public venues and non-essential businesses on COVID-19 vaccine uptake. We use event-study and difference-in-differences approaches exploiting the variation in the timing of these measures across Canadian provinces. We find that the announcement of a vaccination mandate is associated with large increase in new first-dose vaccinations in the first week (more than 50% on average) and the second week (more than 100%) immediately following the announcement. The estimated effect starts waning about six weeks past the announcement. Counterfactual simulations using our estimates suggest that these mandates have led to about 289,000 additional first-dose vaccinations in Canada as of September 30, 2021, which is 1 to 8 weeks after the policy announcements across the different provinces. Time-series analysis corroborates our results for Canada, and we further estimate that national vaccine mandates in three European countries also led to large gains in first-dose vaccinations (7+ mln in France, 4+ mln in Italy and 1+ mln in Germany, 7 to 12 weeks after the policy announcements). NOTE: The reported numbers may change with more data. Please see updated version when available.
Competing Interest Statement
The authors have declared no competing interest.
No funding external to the authors’ home institution was received for this project.
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used in this manuscript is based on information available in public domain. Data sources and links are provided within the manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
Categories: All Posts